Literature DB >> 15128791

The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment.

Annemieke Th den Boer1, Geertje J D van Mierlo, Marieke F Fransen, Cornelis J M Melief, Rienk Offringa, René E M Toes.   

Abstract

Naive T cells can be tolerized in the periphery by diverse mechanisms. However, the extent to which memory T cells are susceptible to tolerance induction is less well defined. Vaccination of mice with a minimal CTL epitope derived from human adenovirus type 5 E1A in IFA s.c. readily tolerizes naive as well as recently activated CD8(+) T cells due to the overwhelming systemic and persistent presence of the peptide. We have now studied the effect of this peptide on established memory cells, which were induced at least 50 days before by virus vaccination. Memory cells did not undergo peripheral deletion and kept their ability to produce IFN-gamma as well as their cytolytic activity in response to Ag directly ex vivo. However, memory CTL responses in virus vaccinated mice injected with peptide ceased to control tumor outgrowth. Interestingly, functional capacities were regained when T cells were transferred to an Ag-free environment in vivo as determined by their ability to reject an otherwise lethal tumor challenge. Together, these findings indicate that memory CTL responses can be functionally incapacitated, but are not, in contrast to naive or recently activated T cells, irreversibly tolerized by persistent systemic Ag, as memory T cells quickly regain effector function upon disappearance of the Ag.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128791     DOI: 10.4049/jimmunol.172.10.6074

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  The speed of change: towards a discontinuity theory of immunity?

Authors:  Thomas Pradeu; Sébastien Jaeger; Eric Vivier
Journal:  Nat Rev Immunol       Date:  2013-09-02       Impact factor: 53.106

2.  Suppression of T-cell expansion by melanoma is exerted on resting cells.

Authors:  Andrew J Russ; Lucy Wentworth; Kyle Xu; Alexander Rakhmilevich; Christine M Seroogy; Paul M Sondel; M Suresh; Clifford S Cho
Journal:  Ann Surg Oncol       Date:  2011-04-05       Impact factor: 5.344

3.  Nucleosides present on phlebotomine saliva induce immunossuppression and promote the infection establishment.

Authors:  Vanessa Carregaro; José M Ribeiro; Jesus G Valenzuela; Djalma L Souza-Júnior; Diego L Costa; Carlo J F Oliveira; Laís A Sacramento; Manuela S L Nascimento; Cristiane M Milanezi; Fernando Q Cunha; João S Silva
Journal:  PLoS Negl Trop Dis       Date:  2015-04-07

4.  Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model.

Authors:  Tullia C Bruno; Cristin Rothwell; Joseph F Grosso; Derese Getnet; Hung Rong Yen; Nicholas M Durham; George Netto; Drew M Pardoll; Charles G Drake
Journal:  Prostate       Date:  2011-07-14       Impact factor: 4.104

Review 5.  CD8+ T-cell memory in tumor immunology and immunotherapy.

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

6.  Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion.

Authors:  Lyndsay Avery; Jessica Filderman; Andrea L Szymczak-Workman; Lawrence P Kane
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-20       Impact factor: 11.205

7.  Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.

Authors:  Katelyn T Byrne; Anik L Côté; Peisheng Zhang; Shannon M Steinberg; Yanxia Guo; Rameeza Allie; Weijun Zhang; Marc S Ernstoff; Edward J Usherwood; Mary Jo Turk
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

Review 8.  Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.

Authors:  Lauren C Harshman; Toni K Choueiri; Charles Drake; F Stephen Hodi
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

Review 9.  Combination immunotherapy approaches.

Authors:  C G Drake
Journal:  Ann Oncol       Date:  2012-09       Impact factor: 32.976

Review 10.  Immunotherapy for prostate cancer: recent developments and future challenges.

Authors:  Michael T Schweizer; Charles G Drake
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.